Many people love the 340B Drug Pricing Program.
CHICAGO—The consequences of diminishing federal support for cancer research can be measured in the abstracts presented at the 50th annual meeting of the American Society of Clinical Oncology that concluded earlier this week.
Confronted with the prospect of censure by an academic freedom group, Ronald DePinho, president of MD Anderson Cancer Center, is defending his decision to deny tenure renewal to two faculty members.
In a long-awaited survey of employees at MD Anderson Cancer Center, faculty members show a significant drop in approval scores for the administration's executive leadership, in comparison with the last time the survey was administered in 2012.
The budgets of operations and statistical centers of adult clinical trials groups were cut by about $20.4 million, group chairs say.
NCI officials said they plan to hold a series of meetings with clinical trials group chairs and group financial officers in order to fine-tune the new National Clinical Trials Network.
A year before Kapil Mehta's tenure term expired last August, the 11-member Promotions and Tenure Committee at MD Anderson Cancer Center had unanimously recommended renewal.
Last week, a blistering opinion piece on The New York Times editorial page focused on the coziness of the relationship between the American Cancer Society and Walgreens. The piece initially triggered criticism by ACS officials, but then—with no fanfare whatsoever—the society’s CEO called on the drug store chain, as well as others, to stop selling tobacco […]
Following an explosion of criticism, NCI said funding for community oncology clinics would not be interrupted.
